ONKURE THERAPEUTICS INC-A (OKUR) Stock Price, Quote, News and Overview
NASDAQ:OKUR - Nasdaq - US68277Q1058 - Common Stock - Currency: USD
OKUR Quote, Performance and Key Statistics
2.4
+0.4 (+20%)
The current stock price of OKUR is 2.4 USD. In the past month the price decreased by -3.61%.
OKUR Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.02 | 355.88B | ||
| AMGN | AMGEN INC | 13.27 | 155.58B | ||
| GILD | GILEAD SCIENCES INC | 15.52 | 149.45B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.37 | 101.67B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.3 | 60.63B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 56.40B | ||
| ARGX | ARGENX SE - ADR | 69.75 | 39.57B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.67 | 33.28B | ||
| BNTX | BIONTECH SE-ADR | N/A | 27.11B | ||
| INSM | INSMED INC | N/A | 23.31B | ||
| NTRA | NATERA INC | N/A | 21.53B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 19.96B |
Related stock screener links
About OKUR
Company Profile
OnKure Therapeutics, Inc. engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company is headquartered in Boulder, Colorado and currently employs 46 full-time employees. The company went IPO on 2021-04-09. Using a structure-based drug design platform, the Company is building a pipeline of tumor-agnostic candidates. The company is developing OKI-219, a selective PI3KaH1047R inhibitor, as its lead program. The company is engaged in targeting oncogenic PI3Ka and has multiple programs designed to enable targeting of this key oncogene. The company is focused on delivering highly selective drug candidates that preserve wild-type PI3Ka while targeting the PI3Ka-mutated cancers, initially in advanced breast cancer. Its lead product candidate, OKI-219, is advancing in a phase I clinical trial. The company also focuses on a development candidate targeting the most common PI3Ka mutations, such as H1047R, E545K, and E542K. Additionally, it is developing an allosteric inhibitor molecule.
Company Info
ONKURE THERAPEUTICS INC-A
6707 Winchester Circle, Suite 400
Boulder COLORADO US
Employees: 46
Phone: 17203072892
ONKURE THERAPEUTICS INC-A / OKUR FAQ
What is the stock price of ONKURE THERAPEUTICS INC-A today?
The current stock price of OKUR is 2.4 USD. The price increased by 20% in the last trading session.
What is the ticker symbol for ONKURE THERAPEUTICS INC-A stock?
The exchange symbol of ONKURE THERAPEUTICS INC-A is OKUR and it is listed on the Nasdaq exchange.
On which exchange is OKUR stock listed?
OKUR stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ONKURE THERAPEUTICS INC-A stock?
12 analysts have analysed OKUR and the average price target is 32.64 USD. This implies a price increase of 1260% is expected in the next year compared to the current price of 2.4. Check the ONKURE THERAPEUTICS INC-A stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ONKURE THERAPEUTICS INC-A worth?
ONKURE THERAPEUTICS INC-A (OKUR) has a market capitalization of 32.42M USD. This makes OKUR a Nano Cap stock.
How many employees does ONKURE THERAPEUTICS INC-A have?
ONKURE THERAPEUTICS INC-A (OKUR) currently has 46 employees.
What are the support and resistance levels for ONKURE THERAPEUTICS INC-A (OKUR) stock?
ONKURE THERAPEUTICS INC-A (OKUR) has a resistance level at 2.41. Check the full technical report for a detailed analysis of OKUR support and resistance levels.
Should I buy ONKURE THERAPEUTICS INC-A (OKUR) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of OKUR, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of OKUR, evaluating the profitability, health, valuation and growth aspects
- ONKURE THERAPEUTICS INC-A (OKUR) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ONKURE THERAPEUTICS INC-A (OKUR) Sales and EPS estimates to see what analysts future expectations are.
- ONKURE THERAPEUTICS INC-A (OKUR) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ONKURE THERAPEUTICS INC-A (OKUR) Insider and Institutional Ownership to learn about the owners and their transactions.
- ONKURE THERAPEUTICS INC-A (OKUR) Stock Chart to make your own analysis
- ONKURE THERAPEUTICS INC-A (OKUR) Latest news and press-releases to stay up to date.
Does ONKURE THERAPEUTICS INC-A (OKUR) stock pay dividends?
OKUR does not pay a dividend.
When does ONKURE THERAPEUTICS INC-A (OKUR) report earnings?
ONKURE THERAPEUTICS INC-A (OKUR) will report earnings on 2025-11-05, before the market open.
What is the Price/Earnings (PE) ratio of ONKURE THERAPEUTICS INC-A (OKUR)?
ONKURE THERAPEUTICS INC-A (OKUR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.8).
What is the Short Interest ratio of ONKURE THERAPEUTICS INC-A (OKUR) stock?
The outstanding short interest for ONKURE THERAPEUTICS INC-A (OKUR) is 2.2% of its float. Check the ownership tab for more information on the OKUR short interest.
OKUR Technical Analysis
OKUR Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to OKUR. OKUR has a great financial health rating, but its profitability evaluates not so good.
OKUR Financial Highlights
Over the last trailing twelve months OKUR reported a non-GAAP Earnings per Share(EPS) of -4.8. The EPS increased by 10.78% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -60.24% | ||
| ROE | -66.38% | ||
| Debt/Equity | 0 |
OKUR Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 85% to OKUR. The Buy consensus is the average rating of analysts ratings from 12 analysts.